The Center for the Biology of Chronic Disease (CBCD) is reporting new developments in genital herpes vaccine research.
The Center for the Biology of Chronic Disease (CBCD) is watching closely the development of a new vaccine to protect against genital herpes. Research is being conducted by William Halford, associate professor of medical microbiology, immunology and cell biology at Southern Illinois University School of Medicine. He is using an approach that includes the weakened, live Herpes virus. The results of his research to date have been published in the March 2011 issue of the scientific journal, PLoS ONE.
However, genetic-engineering techniques available since the 1970s have led to a pervasive view that creating new vaccines with live viruses would be too risky for patients compared with other vaccine-development options. This view is not stopping Professor Halford.
The CBCD encourages all forms of Genital Herpes prevention, including research which, at times, may go against the scientific community’s grain. In fact, the CBCD points to research, which includes alternative means of helping the immune system to lower the concentrations of latent viruses within the body.